Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

1 DEFINITY ® (Package Insert), North Billerica, MA, Lantheus Medical Imaging, Inc., 2017. 2 Parker JM, et al, Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.
Nasdaq

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Medscape

FDA approves new ultrasound contrast agent

Wilmington, DE -DuPont Pharmaceuticals announced today they have received FDA approval for their Definity? (Perflutren Lipid Microsphere) ultrasound contrast agent. Definity is used to improve the ...
Seeking Alpha

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, ...
Nasdaq

Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging ...